benzyl di(prop-2-yn-1-yl)carbamate | 120942-75-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl di(prop-2-yn-1-yl)carbamate
• 英文别名: Di-prop-2-ynyl-carbamic acid benzyl ester；benzyl N,N-bis(prop-2-ynyl)carbamate
• CAS: 120942-75-8
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: FAXMDNGGIKKCNZ-UHFFFAOYSA-N

物化性质

• 沸点：
  336.1±42.0 °C(Predicted)
• 密度：
  1.138±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  benzyl di(prop-2-yn-1-yl)carbamate 在 palladium on activated charcoal 三乙胺 、 potassium iodide 作用下， 以 甲醇 、 乙腈 为溶剂， 25.0 ℃ 、399.99 kPa 条件下， 反应 70.0h， 生成 benzyl 3,4-bis(2-methoxy-2-oxoethyl)pyrrole-1-carboxylate
  参考文献：
  名称：

  Synthesis of Pyrrole-3,4-diacetic Acid and Its Derivatives

  摘要：

  合成吡咯-3,4-二乙酸酯及其N-衍生物的简单程序包括二炔丙胺或N-衍生物的氧化烷氧基羰基化，得到3,4-双(烷氧基羰基亚甲基)吡咯烷，其可以容易地异构化为吡咯- 3,4-二乙酸酯。这些酯的受控水解得到吡咯烷-3,4-二乙酸。

  DOI：

  10.1055/s-1989-27217
• 作为产物：
  描述：

  2-丙炔-1-基氨基甲酸苄酯 、 3-溴丙炔 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 、 甲苯 为溶剂， 生成 benzyl di(prop-2-yn-1-yl)carbamate
  参考文献：
  名称：

  [EN] GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES
  [FR] CONJUGUÉS D'INSULINE SENSIBLES AU GLUCOSE COMPRENANT UN GROUPE DE SUCRE TÉTRAVALENT POUR TRAITEMENT DU DIABÈTE

  摘要：

  An insulin conjugate comprising or consisting of a tetra-valent sugar cluster is described. The tetra-valent sugar cluster connected via a tetra-dentate linker having four arms to the insulin molecule or insulin analog. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose.

  公开号：

  WO2023091441A1

文献信息

• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2009125230A1

  公开（公告）日：2009-10-15

  The invention provides a compound of the formula (1 ): or a salt, solvate, N-oxide or tautomer thereof; wherein either R1 is R1a and R2 is R2a; or R1 is R1b and R2 is R2b; provided that in each case at least one of R1 and R2 is other than hydrogen; R1a and R2a are the same or different and each is selected from hydrogen, C1-4 alkyl, C2-4 alkenyl and C2-4 alkynyl wherein the C1-4 alkyl is optionally substituted by C1-2 alkoxy; R1b and R2b are the same or different and are selected from hydrogen, C(O)NR4R5, C(O)R6 and C(O)OR6 where R6 is C1-4 alkyl, R4 and R5 are both C1-4 alkyl, or NR4R5 forms a 4 to 7 membered saturated heterocyclic ring optionally containing a second heteroatom ring member selected from O, N or S and oxidised forms of N and S, the heterocyclic ring being optionally substituted by one or two C1-4 alkyl groups and/or one or two oxo groups; and R3 is a group (D): wherein the asterisk denotes the point of attachment to the isoindoline ring; but excluding acetic acid 5-acetoxy-4-isopropyl-2-[5-(4-methyl-piperazin-1 -ylmethyl)-1,3- dihydro-isoindole-2-carbonyl]-phenyl ester.

  该发明提供了一个化合物，其化学式为（1）：或其盐、溶剂合物、N-氧化物或互变异构体；其中R1是R1a且R2是R2a；或R1是R1b且R2是R2b；但在每种情况下，R1和R2中至少有一个不是氢；R1a和R2a相同或不同，每个都选自氢、C1-4烷基、C2-4烯基和C2-4炔基，其中C1-4烷基可选择地被C1-2烷氧基取代；R1b和R2b相同或不同，选自氢、C（O）NR4R5、C（O）R6和C（O）OR6，其中R6是C1-4烷基，R4和R5都是C1-4烷基，或NR4R5形成一个含有第二杂原子环成员O、N或S和氮和硫的氧化形式的4到7成员饱和杂环，该杂环可选择地被一个或两个C1-4烷基基团和/或一个或两个氧基团取代；R3是一个基团（D）：其中星号表示与异吲哚啉环的连接点；但不包括乙酸5-乙氧基-4-异丙基-2-[5-(4-甲基哌嗪-1-基甲基)-1,3-二氢-异吲哚-2-羰基]-苯基酯。
• PHARMACEUTICAL COMPOUNDS
  申请人：Congreve Miles Stuart

  公开号：US20100152184A1

  公开（公告）日：2010-06-17

  The invention provides a compound for use in medicine, the compound being a compound of the formula (VI 0 ) or a salt, solvate, tautomer or N-oxide thereof: wherein the bicyclic group: is selected from the structures C1, C5 and C6: wherein n is 0, 1, 2 or 3; R 1 is hydrogen, hydroxy, or O—R z ; R 2a is hydroxy, methoxy or O—R z ; provided that at least one of R 1 and R 2a is O—R z ; R z is L p -R p1 ; SO 3 H; a glucuronide residue; a mono-, di- or tripeptide residue; or L p is a bond, C═O, (C═O)O, (C═O)NR p1 or S(O) x NR p1 ; x is 1 or 2; R p1 is hydrogen or a an optionally substituted C 1-25 hydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that R p1 is not hydrogen when L p is a bond, C═O or (C═O)O; and provided also that O—R z does not contain an O—O moiety; and excluding compounds wherein R 1 is hydroxy and R 2a is methoxy; R p2 and R p3 are the same or different and each is a group R p1 ; and R 3 , R 4a , R 8 and R 10 are defined in the claims. The compounds of formula (VI 0 ) are pro-drugs of parent compounds wherein R 1 and/or R 2a are hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.

  本发明提供了一种用于药物中的化合物，该化合物是式(VI0)的化合物或其盐、溶剂化物、互变异构体或N-氧化物：其中双环基团：选自结构C1、C5和C6：其中n为0、1、2或3；R1为氢、羟基或O—Rz；R2a为羟基、甲氧基或O—Rz；条件是R1和R2a中至少一个是O—Rz；Rz为Lp-Rp1；SO3H；一个葡萄糖苷酸残基；一个单、二或三肽残基；或Lp为键、C═O、(C═O)O、(C═O)NRp1或S(O)xNRp1；x为1或2；Rp1为氢或一个可选地取代的含0、1或2个碳环和0、1、2、3、4、5或6个碳-碳多重键的C1-25烃基团，条件是当Lp为键、C═O或(C═O)O时，Rp1不是氢；并且还条件是O—Rz不包含O—O部分；并排除R1为羟基且R2a为甲氧基的化合物；Rp2和Rp3相同或不同，且各自为Rp1基团；R3、R4a、R8和R10如权利要求中定义。式(VI0)的化合物是其中R1和/或R2a为羟基的母化合物的前药，其中母化合物具有Hsp90抑制活性。
• [EN] INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X<br/>[FR] INHIBITION DE LA PEPTIDASE 9X SPÉCIFIQUE DE L'UBIQUITINE
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2020139916A1

  公开（公告）日：2020-07-02

  The disclosure provides novel chemical compounds useful as inhibitors of ubiquitin specific peptidase 9X (USP9X). USP9X inhibiting compounds are useful in the treatment of disease and disorders associated with modulation of USP9X, such as cancer.

  该披露提供了一种新颖的化合物，可用作泛素特异性蛋白酶9X（USP9X）的抑制剂。抑制USP9X的化合物在治疗与调节USP9X相关的疾病和紊乱，如癌症，方面是有用的。
• [EN] ISOINDOLINE DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOINDOLINE
  申请人：VIIV HEALTHCARE UK LTD

  公开号：WO2017093937A1

  公开（公告）日：2017-06-08

  Compounds of Formula (I) are disclosed and methods of treating viral infections with compositions comprising such compounds.

  公式（I）的化合物已被披露，并提供了使用含有这些化合物的组合物治疗病毒感染的方法。
• Synthesis of [2,3]-fused bicyclic cyclopentadiene derivatives by the cycloaddition reaction of diyne with methylmanganese carbonyl complex
  作者：Soon Hyeok Hong、Young Keun Chung

  DOI：10.1016/s0040-4039(98)00917-4

  日期：1998.7

  Methylmanganese pentacarbonyl-mediated transformation of diyne to [2,3]-fused bicyclic cyclopentadienes has been carried out.

  已经进行了甲基锰五羰基介导的二炔向[2，3]-稠合的双环环戊二烯的转化。